Global Myelodysplastic Syndrome Treatment Market, by Drug (Lenalidomide, Decitabine, Azacitidine, and Phase 3 Drugs), by Route of Administration (Injection and Oral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 3,265.6 Million in 2022 and is expected to exhibit a CAGR of 9.3% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
Increasing research and development for the novel drug therapy used in the treatment of Myelodysplastic Syndrome is expected to drive the market growth over the forecast period. For instance, in December 2021, OncLive Peer Exchange, an organization panel of hematologic cancer experts shared their insights on the most recent the US Food and Drug Administration-approved agents for Myelodysplastic Syndrome, including luspatercept and decitabine/cedazuridine (Inqovi), both of which were approved in 2020. More recently, several agents for specific patient subgroups have been approved by the US Food and Drug Administration, including for patients with very low-risk to high-risk MDS, and many other novel agents with unique mechanisms of action are on the horizon.
Moreover, in April 2020, the U.S. Food and Drug Administration (FDA) approved Reblozyl (luspatercept-aamt), the first and only Erythroid Maturation Agent, to treat anemia in adults with Lower-Risk Myelodysplastic Syndromes (MDS).
Global Myelodysplastic Syndrome Treatment Market– Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions. Private healthcare is one such sector that has been impacted significantly by the COVID-19 pandemic.
However, the COVID-19 pandemic had a negative impact on the global myelodysplastic syndrome treatment market, owing to decrease in the supply of the drugs used in the treatment of Myelodysplastic Syndrome. For instance, in July 2020, according to the National Center for Biotechnology Information, the impact of the measures implemented to address the COVID-19 pandemic appear to have been most homogenous to date at the very end of the drug supply chain, in the destination markets. The overall impact on bulk supply is reportedly more heterogenous, both across drugs and across countries. Increased controls resulting from the implementation of measures to fight the spread of COVID-19 have had double-edged consequences on large-scale drug supply. There have also been reports of organized criminal groups involved in drug trafficking becoming distracted from their usual illicit activities by emerging crime linked to the COVID-19 pandemic; for example, cybercrime and trafficking in falsified medicines in the Balkan countries.
Global Myelodysplastic Syndrome Treatment Market: Key Developments
In May 2021, Novartis, a pharmaceutical company, received the U.S. Food and Drug Administration (FDA) fast track designation for sabatolimab (MBG453) for the treatment of adult patients with myelodysplastic syndromes (MDS) defined with an IPSS-R risk category of high or very high risk in combination with hypomethylating agents. Fast track designation facilitates the development and expedites the review of drugs to treat serious conditions and fulfill unmet medical needs. Sabatolimab is a first-in-class investigational immuno-myeloid therapy that binds to TIM-3, a novel target expressed on multiple immune cell types and leukemic cells and blasts, but not on the normal stem cells that induce blood formation. It is in development for Myelodysplastic syndromes and acute myeloid leukemia (AML).
In February 2022, the U.S. Food and Drug Administration (FDA) had granted orphan drug designation (ODD) to Syros Pharmaceuticals’ oral therapy, tamibarotene, to treat myelodysplastic syndrome (MDS). Tamibarotene is a selective retinoic acid receptor alpha (RARα) agonist. Tamibarotene is currently being analyzed along with azacitidine in the Phase III SELECT-MDS-1 trial.
Browse 32 Market Data Tables and 35 Figures spread through 255 Pages and in-depth TOC on “Global Myelodysplastic Syndrome Treatment Market”- Forecast to 2030, Global Myelodysplastic Syndrome Treatment Market, by Drug (Lenalidomide, Decitabine, Azacitidine, and Phase 3 Drugs), by Route of Administration (Injection and Oral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/myelodysplastic-syndrome-treatment-market-775
Key Takeaways of the Global Myelodysplastic Syndrome Treatment Market:
- Global myelodysplastic syndrome treatment market is expected to exhibit a CAGR of 9.3% during the forecast period due to the increasing adoption of inorganic strategies such as collaborations and agreements by key players in market for developing drugs for treatment of Myelodysplastic syndrome. For instance, in December 2018, Celgene Corporation in collaboration with Acceleron Pharma Inc. announced the results from the pivotal, phase 3 MEDALIST trial. Moreover, players in the MDS treatment market such as Celgene are focused on investing in research and development (R&D) of MDS specific drugs and several of their drugs are showing positive results in the clinical trials. For instance, according to the Celgene, Pharmaceutical Company May 2017, the company had gained the information about the role of innate immune system in the development of MDS. Celgene is currently focused on Research &Development to target this particular type of inflammation with medications and therapeutic antibodies, in order to make MDS cells more vulnerable. These factors are expected to drive growth of the myelodysplastic syndrome treatment market over the forecast period.
- Among regions, North America is estimated to account for the largest market share in the global myelodysplastic syndrome treatment market over the forecast period, owing to the increasing prevalence of myelodysplastic syndrome. For instance, in November 2021, according to the data published by National Center for Biotechnology Information, in the US, in 2021, 20,000 new cases are reported every year in the US, making MDS one of the most common blood cancers. The prevalence of MDS has been poorly assessed, but is estimated to be between 60,000 – 170,000 patients in the U.S. Advanced age is the predominate risk factor, with a median age of diagnosis of 71-76 years. The overall incidence of MDS in the U.S. is estimated at close to four cases per 100,000 people, with as many as 20,000 to 30,000 people diagnosed annually.
- Major players operating in the global myelodysplastic syndrome treatment market include Celgene Corporation, Otsuka Pharmaceutical Co., Ltd. Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd., Mylan NV, Cipla Limited, Acceleron Pharma, Inc., Aprea Therapeutics, FibroGen Inc., Onconova Therapeutics Inc., and Geron
